Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Derma Sciences: Close to Upgrading (DSCI, $4.54)

Investment Perspective

With the failure of its biotechnology drug candidate aclerastide, Derma Sciences is abandoning drug development efforts. The Company…
Read more…

Derma Sciences: Sales Guidance for 2014 is Lowered Again; 2015 Sales Guidance is Given for the First Time (DSCI, Hold, $9.40)

Derma Sciences announced preliminary sales results for 2014 of $83.7 million which represents a 5% increase over 2013. This was…
Read more…

Derma Sciences: Second Quarter Results Were Disappointing; Going From a Buy to a Hold (DSCI, $9.72)

Derma Sciences released second quarter results this morning and this is my quick take. I will have a more detailed…
Read more…

Derma Sciences: Highlights of the June 17th Analystsí Meeting (DSCI, Buy, $11.07, Free content)

Price Target Thinking

In my initiation report of January 31, 2014, I argued for a 2018 price target of $20 to…
Read more…

Derma Sciences: An Update and Re-iteration of Buy Recommendation (DSCI, Buy $9.50, For Paid Subscribers)

Investment Perspective in Brief

I am re-iterating my Buy recommendation on Derma Sciences (DSCI) as I believe that it presents an…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Ed Quilty, CEO of Derma Sciences, Outlines His Strategy to Build the Premier Wound Healing Company (DSCI, $12.00)

Investment Thesis

I published an extensive report on Derma Sciences (DSCI) on January 31, 2014 in which I recommended purchase. I…
Read more…

SmithOnStocks Mailbox February 25, 2014

I have found that there are some very smart people out there who have interesting questions and perspectives concerning my…
Read more…

Derma Sciences: An In-Depth Look at An Emerging Growth Stock (DSCI, $12.77) (Subscribers Only)

Investment Perspective in Brief

Derma Sciences presents an unusual and attractive biotechnology investment situation. We are all aware of the binary…
Read more…

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

What SmithOnStocks Is All About
It is traditional at the start of the year to go over stock picks for the…
Read more…